Search

Lichen planus is a benign inflammatory disorder of unknown etiology that may affect the skin, mucosae, scalp, and nails. When the nails are affected, it may lead to permanent destruction with severe functional and psychosocial consequences. Therefore, prompt diagnosis and early treatment are essential, even in mild cases. There are currently no guidelines for the management of nail lichen planus and the published literature on treatment is limited. The aim of this review is to provide practical management recommendations for the classical form of nail lichen planus, especially when restricted to the nails. Topical treatment has poor short-term efficacy and may cause long-term side effects. Instead, intralesional and intramuscular triamcinolone acetonide should be considered first-line therapies. Oral retinoids are second-line choices, and immunosuppressive agents may also be considered., SCOPUS: re.j, info:eu-repo/semantics/published

FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV).To further evaluate the efficacy and safety of FMX101 4% in treating moderate to severe acne vulgaris.A 12-week, multicenter, randomized (1:1), double-blind, vehicle-controlled study was conducted. Coprimary end points were the absolute change in inflammatory lesion count from baseline and the rate of treatment success (Investigator's Global Assessment score of 0 or 1 with a ≥2-grade improvement).There were 1488 participants in the intent-to-treat population. The FMX101 4% group had significantly greater reductions in the number of inflammatory lesions from baseline (P .0001) and a greater rate of treatment success based on Investigator's Global Assessment (P .0001) versus the foam vehicle group at week 12. FMX101 4% was generally safe and well tolerated.The efficacy and safety of FMX101 4% were not characterized in participants with mild AV.FMX101 4% topical minocycline foam was effective and safe for the treatment of moderate to severe AV.

mis, and subcutaneous fat without evidence of epidermotropism.2, 5, 7 Our patient demonstrates that ~//8 CTCL can present both clinically and histologically as typical mycosis fungoides. This supports the view that definition of a new clinicopathologic entity is not indicated.6, 8 However, the rapid progression described in this patient, which is not often seen in mycosis fungoides, may be related to the nature of these cells; ",//8 TCR rearrangement occurs earlier during T-cell maturation in the thymus. If this rearrangement fails, call3 TCRs are expressed. 11 CD7 is also an early marker of T-cell differentiation. Therefore T cells expressing CD7 and ~/Ki TCR can be regarded as less mature and may respond differently to the various cytokines presumed to play a role in the progression of mycosis fungoides. 12 The altered response may lead to either spread of the eruption or to the development of tumors within a short period, thus resulting in more aggressive behavior.